Technical Analysis for ZFGN - Zafgen, Inc.

Grade Last Price % Change Price Change
grade F 2.84 -5.02% -0.15
ZFGN closed down 5.02 percent on Friday, March 22, 2019, on approximately normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical ZFGN trend table...

Date Alert Name Type % Chg
Mar 22 New 52 Week Closing Low Bearish 0.00%
Mar 22 Wide Bands Range Expansion 0.00%
Mar 22 Oversold Stochastic Weakness 0.00%
Mar 21 Narrow Range Bar Range Contraction -5.02%
Mar 21 NR7 Range Contraction -5.02%
Mar 21 Wide Bands Range Expansion -5.02%
Mar 21 Oversold Stochastic Weakness -5.02%
Mar 20 Calm After Storm Range Contraction -4.70%
Mar 20 Narrow Range Bar Range Contraction -4.70%
Mar 20 Doji - Bullish? Reversal -4.70%

Older signals for ZFGN ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Zafgen, Inc. is a biopharmaceutical company. The Company is engaged in improving the health and well-being of patients affected by obesity. Beloranib, the Company’s product candidate, is a twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including obesity and hyperphagia, or insatiable life-threatening hunger and hunger-related behaviors, in Prader-Willi Syndrome (PWS), craniopharyngioma-associated obesity, and severe obesity in the general population. PWS is a rare and complex genetic disorder characterized by physiologic, cognitive and behavioral symptoms, including hyperphagia and obesity. Craniopharyngioma is a rare form of benign brain tumor that occurs near the optic nerve, pituitary gland and hypothalamus. Approximately 30% to 50% of cases of craniopharyngioma are diagnosed in childhood and adolescence.
Medicine Biopharmaceutical Organ Systems Obesity Neuroendocrinology Prader Willi Syndrome
Is ZFGN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 12.355
52 Week Low 2.78
Average Volume 295,962
200-Day Moving Average 7.6982
50-Day Moving Average 4.3256
20-Day Moving Average 3.9105
10-Day Moving Average 3.136
Average True Range 0.2517
ADX 36.25
+DI 12.6924
-DI 42.5777
Chandelier Exit (Long, 3 ATRs ) 4.2349
Chandelier Exit (Short, 3 ATRs ) 3.5351
Upper Bollinger Band 5.6174
Lower Bollinger Band 2.2036
Percent B (%b) 0.19
BandWidth 87.298299
MACD Line -0.4866
MACD Signal Line -0.3793
MACD Histogram -0.1073
Fundamentals Value
Market Cap 78.05 Million
Num Shares 27.5 Million
EPS -1.88
Price-to-Earnings (P/E) Ratio -1.51
Price-to-Sales 0.00
Price-to-Book 0.95
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.13
Resistance 3 (R3) 3.15 3.09 3.08
Resistance 2 (R2) 3.09 3.01 3.07 3.06
Resistance 1 (R1) 2.96 2.97 2.93 2.94 3.05
Pivot Point 2.90 2.90 2.88 2.88 2.90
Support 1 (S1) 2.77 2.82 2.74 2.75 2.63
Support 2 (S2) 2.71 2.78 2.69 2.62
Support 3 (S3) 2.58 2.71 2.60
Support 4 (S4) 2.56